Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

ENDRA's Pending Noble Africa Merger Shows Small-Cap Deal Fatigue on a Crowded M&A Day

ENDRA's Q3 shows merger fees rising as R&D falls while the Noble Africa deal awaits closing conditions, and peers show how varied small-cap exit routes have become.

17 Nov 2026 · CompePharma editorial

What happened

ENDRA Life Sciences, developer of a liver-fat imaging technology, reported a Q3 net loss of $1.5m. The detail that matters for the deals desk is the mix. Merger-related fees pushed general and administrative costs higher, while R&D spending fell. The proposed transaction with Noble Africa, a subsidiary of ASP Isotopes, is still pending approvals and other closing conditions.

The material we have does not disclose the deal's terms, the size of the fees, or the approvals still outstanding, so we do not speculate on them. What the quarter does show is a company whose cost base is tilting from development toward transaction execution while the outcome remains open.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →